Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Pethidine hydrochloride may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Pethidine Injection is a type of medicine called an opioid analgesic. It contains pethidine which belongs to a class of medicines called opioids, which are 'pain relievers. An analgesic is a medicine that can be used to relieve pain. This medicine has been prescribed for you for relief of moderate to severe pain. Including pain associated with childbirth, or during an anaesthetic or following an operation. As well as relieving pain, pethidine has other effects including a sedative (calming) effect. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.
Pethidine Injection You should not be given Pethidine Injection
depression), coma and may be fatal. Even if benzodiazepines are prescribed, your doctor may need to change the dose, the duration of treatment or monitor you regularly. Talk to your prescriber before taking this medicine if you:
are or have ever been addicted to opioids, alcohol, prescription medicines, or illegal drugs. have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating when you have stopped taking alcohol or drugs feel you need to take more of Pethidine Injection to get the same level of pain relief, this may mean you are becoming tolerant to the effects of this medicine or are becoming addicted to it. Speak to your prescriber who will discuss your treatment and may change your dose or switch you to an alternative pain reliever.
Taking this medicine regularly, particularly for a long time, can lead to addiction. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely. Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. If you are elderly or ill, or your baby or child is being given Pethidine Injection, special care will be taken. This medicine may cause difficulty in breathing (respiratory depression) in neonates and young infants. If any of the above apply to you or your child, please tell your doctor before being given Pethidine Injection. Other medicines and Pethidine Injection Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Pethidine Injection must not be used with drugs used to treat severe depression, such as rasagiline or moclobemide, or if you are within 2 weeks of discontinuing them.
A large number of drugs can interact with Pethidine Injection which can significantly alter their effects. These drugs include:
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Pregnancy Do not take Pethidine Injection if you are pregnant or think you might be pregnant unless you have discussed this with your prescriber and the benefits of treatment are considered to outweigh the potential harm to the baby. If you use Pethidine Injection during pregnancy, your baby may become dependent and experience withdrawal symptoms after the birth which may need to be treated. Pethidine Injection may cause breathing problems in newborns. Breast-feeding Do not take Pethidine Injection while you are breastfeeding as pethidine passes into breast milk and will affect your baby. Driving and using machines Pethidine Injection can cause drowsiness and clouding of consciousness which could interfere with your ability to use machines. Do not operate machinery whilst you are taking this medicine. When your Pethidine Injection treatment has stopped, ask your doctor when it will be safe for you to use machines. The medicine can affect your ability to drive as it may make you sleepy or dizzy.
to you
Pethidine Injection may be administered by injection into a muscle (intramuscular), or into the tissue just below the skin (subcutaneous) or by slow injection into the vein (intravenous). Your prescriber should have discussed with you, how long the course of injection will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. Adults: A single dose of between 25 – 100mg may be injected into a muscle or into the tissue just beneath the skin. For injection into a vein, a single dose of between 25 – 50mg may be given slowly. These single doses should not usually be repeated more frequently than every 4 hours if required. Elderly Patients or for Patients in a Weakened Condition: The initial dose should not exceed 25mg, because elderly patients or those in a weakened condition are more sensitive to the unwanted effects of pethidine. Use in children The usual single dose is 0.5 to 2.0mg per kilogram of body weight by injection into a muscle. If necessary, this dose may be repeated, allowing at least 4 hours between doses. To ensure that the correct dose is given, use of a special syringe with fine markings is recommended for administration in children. Alternatively, the solution may be diluted in Water for Injections to make it easier to measure the dose accurately. If you have any further questions on the use of this product, ask your doctor or pharmacist. If you think you have been given more Pethidine Injection than you should The symptoms and signs of taking too much of this medicine include shallow breathing, drowsiness, incoordination, coma, seizures, blue skin and lips, eye closure (miosis), shaking, cold, clammy skin, drop in body temperature, slow heartbeat and low blood pressure. This medicine will be given to you in hospital so it is unlikely you will receive too much. Your doctor has information on how to recognise and treat an overdose. If you feel unwell after being given this medicine, or are at all concerned you have been given too much, tell your doctor or nurse immediately. If you think you have missed a dose of Pethidine Injection Tell your doctor, nurse immediately. If you have any further questions on the use of this medicine, ask your doctor or nurse. If you stop taking Pethidine Injection Do not suddenly stop taking this medicine. If you want to stop taking this medicine, discuss this with your prescriber first. They will tell you how to do this, usually by reducing the dose gradually so that any unpleasant withdrawal effects are kept to a minimum. Withdrawal symptoms such as restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating may occur if you suddenly stop taking this medicine.
If you have any further questions on the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everyone gets them. Repeated use of pethidine can result in tolerance and addiction These are more common when Pethidine is given into a vein. All medicines can cause allergic reactions although serious allergic reactions are rare. Any sudden wheeziness and tightness of the chest, difficulty in breathing, swelling of the eyelids, face or lips, skin lumps or hives, skin rash (red spots) or itching (especially affecting your whole body), fever and collapse should be reported to a doctor immediately. The most serious side effects are difficulty breathing and low blood pressure. Other side effects that may occur include: Uncommon: may affect up to 1 in 100 people:
Pethidine Injection Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and ampoule label after 'Exp'. The expiry date refers to the last day of that month. Do not store above 25°C. Keep the ampoules in the outer carton in order to protect from light. The product should not be used after the expiry date printed on the ampoule or carton. If only part of the contents of an ampoule is used, the remaining solution should be discarded.
What Pethidine Injection contains
Pethidine Injection BP 50mg/ml comes as injection containing 50mg/ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Pethidine Injection BP 50mg/ml is pethidine hydrochloride.
This leaflet reproduces the patient information leaflet approved for Pethidine Injection BP 50mg/ml, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Pethidine hydrochloride may be used as an analgesic for the relief of moderate to severe pain including: obstetric analgesia; pre-operative medication and analgesia during anaesthesia; post-operative analgesia.
Posology
Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with pethidine in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).
Adults
The following single doses may be used and should not usually be repeated more frequently than four hourly; Subcutaneous or intramuscular injection: 25 - 100mg. Intravenous injection: 25 - 50mg.
Elderly or debilitated patients
The initial dose should not exceed 25mg, because of the particular sensitivity among elderly or debilitated patients to the central depressant effects of pethidine.
Paediatric population
The usual single dose is 0.5 to 2mg/kg body weight by intramuscular injection. If necessary, this dose may be repeated, allowing a minimum of four hours between doses. Use of a small graduated syringe is recommended for the accurate administration of dosages in children. In the absence of graduated syringes, the solution should be diluted with Water for Injections before measuring the dose.
Method of administration
Pethidine Injection may be administered by subcutaneous, intramuscular or slow intravenous injection.
• Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Use of pethidine should be avoided in patients with diabetic acidosis where there is danger of coma.
• In comatose patients
• It also contra-indicated in conditions associated with raised intracranial pressure and in head injury (opioid analgesics interfere with pupillary responses vital for neurological assessment).
• Use of pethidine in patients with Phaeochromocytoma may result in hypertensive crisis.
• Acute respiratory depression, severe obstructive airways disease or acute asthma and when there is risk of paralytic ileus or obstructive airways disease.
• Use in patients receiving monoamine oxidase inhibitors (including moclobemide, and the monoamine B inhibitors selegiline and rasagiline) or within two weeks following their withdrawal.
• It should not be administered to patients with severe renal impairment or severe hepatic impairment.
• Should be avoided in patients with acute alcoholism, delirium tremens or in those with convulsive states such as status epilepticus.
• Pethidine should not be administered to patients receiving ritonavir and isoniazid.
• Use of pethidine should be avoided in patients with supraventricular tachycardia.
Pethidine is controlled under the Misuse of Drugs Act 1971 (Schedule 2).
If the intravenous route is being used, pethidine should be given slowly in order to reduce the risk of adverse reactions.
Extreme care is required when administering pethidine to patients with asthma, severe cor pulmonale or reduced respiratory function.
Pethidine should be used with caution or in reduced doses in patients with myasthenia gravis. Pethidine should only be used with caution and in reduced dosage in neonates and premature infants, elderly and debilitated patients and in patients with head injuries, severe hepatic or renal impairment. Renal impairment may result in accumulation of the potentially toxic metabolite norpethidine, particularly with repeat dosing. All of these patient groups may experience increased or prolonged effects of the product.
Pethidine should be used with caution in patients with hypothyroidism, adrenocortical insufficiency, shock, and supraventricular tachycardia.
Although less spasmogenic than morphine, pethidine may precipitate spasm of the ureter or Sphincter of Oddi. Subsequently it should be used with caution in patients with prostatic hypertrophy and biliary tract disorders including those with pain secondary to gallbladder pathology.
Caution is also required in patients with acute alcoholism, raised intracranial pressure, or history of convulsive disorders, existing hypotension as it may reduce the blood pressure further, myasthenia gravis.
In addition it should be avoided in patients with obstructive or inflammatory bowel disorders due to its effects on the gastrointestinal tract where it may precipitate toxic megacolon.
Drug dependence, tolerance and potential for abuse
For all patients, prolonged use of this product may lead to drug dependence (addiction), even at therapeutic doses. The risks are increased in individuals with current or past history of substance misuse disorder (including alcohol misuse) or mental health disorder (e.g., major depression).
Additional support and monitoring may be necessary when prescribing for patients at risk of opioid misuse.
A comprehensive patient history should be taken to document concomitant medications, including over-the-counter medicines and medicines obtained on-line, and past and present medical and psychiatric conditions.
Patients may find that treatment is less effective with chronic use and express a need to increase the dose to obtain the same level of pain control as initially experienced. Patients may also supplement their treatment with additional pain relievers. These could be signs that the patient is developing tolerance.
The risks of developing tolerance should be explained to the patient.
Overuse or misuse may result in overdose and/or death. It is important that patients only use medicines that are prescribed for them at the dose they have been prescribed and do not give this medicine to anyone else.
Patients should be closely monitored for signs of misuse, abuse, or addiction.
The clinical need for analgesic treatment should be reviewed regularly.
Drug withdrawal syndrome
Prior to starting treatment with any opioids, a discussion should be held with patients to put in place a withdrawal strategy for ending treatment with Pethidine.
Drug withdrawal syndrome may occur upon abrupt cessation of therapy or dose reduction. When a patient no longer requires therapy, it is advisable to taper the dose gradually to minimise symptoms of withdrawal. Tapering from a high dose may take weeks to months.
The opioid drug withdrawal syndrome is characterised by some or all of the following: restlessness, lacrimation, rhinorrhoea, yawning, perspiration, chills, myalgia, mydriasis and palpitations. Other symptoms may also develop including irritability, agitation, anxiety, hyperkinesia, tremor, weakness, insomnia, anorexia, abdominal cramps, nausea, vomiting, diarrhoea, increased blood pressure, increased respiratory rate or heart rate.
If women take this drug during pregnancy, there is a risk that their newborn infants will experience neonatal withdrawal syndrome.
Hyperalgesia
Hyperalgesia may be diagnosed if the patient on long-term opioid therapy presents with increased pain. This might be qualitatively and anatomically distinct from pain related to disease progression or to breakthrough pain resulting from development of opioid tolerance. Pain associated with hyperalgesia tends to be more diffuse than the pre-existing pain and less defined in quality. Symptoms of hyperalgesia may resolve with a reduction of opioid dose.
Risk from concomitant use of sedative medicines such as benzodiazepines or related drugs:
Concomitant use of Pethidine and sedative medicines such as benzodiazepines or related drugs may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedative medicines should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe Pethidine concomitantly with sedative medicines, the lowest effective dose should be used, and the duration of treatment should be as short as possible.
The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).
Paediatric population
Pethidine has a slower elimination rate and a larger inter-subject variability in neonates and young infants compared to older children and adults, which may lead to dose related reactions such as respiratory depression. If pethidine use is contemplated in neonates or young infants (up to 12 months), any potential benefits of the drug need to be weighed against the relative risk to the patient.
This medicine contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially 'sodium-free'.
Monoamine Oxidase Inhibitors
The concurrent use of MAOIs (including moclobemide) is contra-indicated (see section 4.3) as they may result in CNS excitation or depression.
Very severe reactions including coma, respiratory depression, cyanosis and hypotension have occurred in patients administered monoamine inhibitors (MAOIs). Pethidine should not be administered to patients taking MAOIs or to those who have taken MAOIs within 14 days (see section 4.3). The interaction of pethidine with MAOIs may result in Serotonin syndrome.
CNS depressants
The central depressant effects of pethidine may be potentiated by the concurrent use of other central nervous system depressants including anxiolytics and sedatives, hypnotics, barbiturates and tricyclic antidepressants, other analgesics, alcohol and general anaesthetics; respiratory depression, hypotension and profound sedation or coma may result.
Opioid agonists
Additive effects on CNS depression, respiratory depression and hypotension can occur with concomitant use of opioid agonist analgesics.
MAO-B inhibitors
Concomitant use of MAO-B inhibitors such as selegiline or rasagiline is contraindicated (see section 4.3) as this may lead to hyperpyrexia and CNS toxicity.
Rasagiline should not be given with pethidine as there is risk of CNS toxicity, its use should be avoided for two weeks after taking rasagiline.
Anticonvulsants
Administration of phenytoin may cause an increase in hepatic metabolism of pethidine and subsequently increased levels of norpethidine (a toxic metabolite).
Antipsychotics
Severe hypotension may occur when pethidine is administered to patients whose ability to maintain blood pressure has been compromised by a depleted blood volume or by the administration of drugs such as phenothiazine.
Histamine H2 antagonists
Cimetidine inhibits metabolism of pethidine and therefore increases plasma concentration.
Anti-virals
Plasma concentrations of pethidine may be decreased by concomitant administration of ritonavir, however levels of norpethidine (a toxic metabolite) may rise. Concomitant administration of ritonavir, isoniazid and pethidine should be avoided (see section 4.3).
Effects of pethidine on other drugs
Pethidine antagonize effects of domperidone and metoclopramide on gastro-intestinal activity.
The plasma levels of ciprofloxacin may be reduced in the presence of opiate premedicants.
Plasma levels of mexiletine may also be reduced in the presence of opioid analgesics. Use of pethidine in prolonged increasing dosage or concomitantly with anticholinergics may result in neurotoxicity in patients with renal failure, cancer or sickle cell anaemia.
Pethidine when given with duloxetine (SSRIs) may increase serotonergic effects.
Sedative medicines such as benzodiazepines or related drugs:
The concomitant use of opioids with sedative medicines such as benzodiazepines or related drugs increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. The dose and duration of concomitant use should be limited (see section 4.4).
Pregnancy
There is inadequate evidence of safety in human pregnancy, but the drug has been in widely use for many years without apparent ill consequence. Animal studies have not shown any hazard.
As with all drugs during pregnancy care should be taken in assessing the risk to benefit ratio.
Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate.
If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.
Breast-feeding
Administration to nursing women is not recommended as pethidine may be secreted in breast milk and may cause respiratory depression in the infant.
This should be borne in mind when considering its use in patients during pregnancy or breast feeding.
Fertility
No data available
Pethidine may impair the mental and/or physical abilities required for driving or for operating machinery. Patients should be advised accordingly and warned not to drive or to operate machines while taking pethidine as it may cause drowsiness and reduce alertness.
The ability to drive or use machines may be severely affected during and for some time after administration of pethidine. This medicine can impair cognitive function and can affect a patient's ability to drive safely. This class of medicine is in the list of drugs included in regulations under 5a of the Road Traffic Act 1988. When prescribing this medicine, patients should be told:
• The medicine is likely to affect your ability to drive
• Do not drive until you know how the medicine affects you
• It is an offence to drive while under the influence of this medicine
• However, you would not be committing an offence (called 'statutory defence') if:
o The medicine has been prescribed to treat a medical or dental problem and
o You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and It was not affecting your ability to drive safely
The information below lists reported adverse reactions, ranked using the following frequency classification:
Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
System Organ Class
Frequency
Adverse Event
Immune system disorders
Not known
General hypersensitivity reactions
Psychiatric disorders
Not known
Drug dependence (see section 4.4), confusion, mood altered, mild euphoria, hallucinations, dysphoria, agitation, anxiety, nervousness. Increased risk of delirium in elderly patients.
Nervous system disorders
Not known
Drowsiness, dizziness, tremor, convulsions, headache, CNS excitation, syncope, light-headedness, sedation
Eye disorders
Not known
Visual disturbances, dry eye, miosis
Ear and labyrinth disorders
Not known
Vertigo
Cardiac disorders
Not known
Tachycardia, bradycardia, palpitations
Vascular disorders
Not known
Flushing of face, orthostatic hypotension, hypotension1, hypertension, vasodilatation
Respiratory, thoracic and mediastinal disorders
Not known
Respiratory depression1
Gastrointestinal disorders
Not known
Nausea, vomiting, dry mouth, constipation
Hepatobiliary disorders
Not known
Biliary or Ureteric spasm
Skin and subcutaneous tissue disorders
Not known
Sweating, rash, urticaria, pruritis
Musculoskeletal and connective tissue disorders
Not known
Uncoordinated muscle movements, muscle twitching
Renal and urinary disorders
Not known
Difficulty in micturition, renal colic, urinary retention
Reproductive system and breast disorders
Not known
Sexual dysfunction
General disorders and administration site conditions
Uncommon
Not known
Drug withdrawal syndrome
Hypothermia, weakness, injection site reactions including pain, induration and irritation, wheal and flare over the vein with intravenous injection
Investigations
Not known
Corneal reflex decreased
1The most serious adverse effects of pethidine are respiratory depression and hypotension. Rapid intravenous administration of pethidine increases the incidence of these effects and may result in serious respiratory depression and hypotension with tachycardia.
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Yellow Card Scheme
Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
Symptoms
Signs of acute overdosage may include respiratory depression, CNS depression with extreme somnolence progressing to incoordination, stupor or coma, convulsions, CNS stimulation, cyanosis, miosis, skeletal muscle flaccidity or tremors, cold, clammy skin, hypothermia, bradycardia, hypotension and shock.
In severe overdosage, apnoea, circulatory collapse, pulmonary oedema, mydriasis, cardiac arrest and death may occur.
Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.
Management
Treatment is supportive. Primary attention should be directed at correcting respiratory failure and shock. A patent airway should be established and assisted or controlled ventilation should be provided. If signs of CNS toxicity are exhibited the use of pethidine should be discontinued. Narcotic antagonists may be required if there is evidence of significant respiratory or cardiovascular depression.
Naloxone is a specific antidote used to counteract respiratory depression and coma resulting from opioid overdosage. Naloxone should be given intravenously as soon as possible and repeated every 2-3 minutes if necessary.
Intravenous fluids, oxygen, vasopressors and other supportive measures may be required in the management of shock. An anticonvulsant may be required if seizures occur.
Medicines sold in Romania with the same active substance: Cunoscut în România ca
Same active substance. The strength, the form and whether you need a prescription can differ. Always ask a pharmacist before you switch. Romanian medicines in the UK →
Ask anything about Pethidine Injection BP 50mg/ml. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.